Biotechnology stocks have fallen out of favor for a number of reasons:

• because bioengineered product tends to be more expensive than chemically created drugs;
• cash strapped status of state and federal governments;
• a string of set backs in clinical trials in the past six months.

Also hurting the overall sector is that the oldest and most successful biotech firm, Genentech, was acquired in 2009 by F. Hoffmanm-LaRoche Ltd.. Since many of these companies are far from their 52 week highs, buying opportunities exist for the right situations. I will look at five established biotechs with a focus on their metrics and pipelines, to ascertain buying opportunities.

Human Genome Sciences, Inc. (HGSI)

I decided to include HGSI